Investment Stage – Series A & B
Carrick Therapeutics is building an innovative portfolio of first-in-class cancer treatments that target multiple mechanisms of the most aggressive forms.
Carrick Therapeutics Website
Spex Capital Ltd. (SPEX), registered in England and Wales, is authorised and regulated by the Financial Conduct Authority having Firm Reference Number 963796.
©2023 · Spex Capital
©2022 · Spex Capital